China Economy: News & Discussion

[ym888]

Are we talking about yet another technology stealing company?

https://www.fiercepharma.com/regulatory/u-s-based-chinese-researcher-pleads-guilty-united-imaging-healthcare-bribery-case

You think American patients will use machines from a Chinese thief company?

China's "intelligent" high-end medical equipment has entered the core area of New York, and the overseas development of United Film Medical has accelerated

2022-11-01 20:44:01

Recently, The first 75cm ultra-large aperture 3.0T magnetic resonance uMR Omega, ultra-high-end 640-slice CT Tianhe 640 and intelligent digital PET-CT uMI 550 independently developed by Shanghai Lianying Medical Technology Co., LTD. (hereinafter referred to as "Lianying Medical") have successively entered AMRIC in the Upper East Side of Manhattan, New York, USA (Advanced Medical & Research Imaging Center), this is the first time that China's high-end medical equipment has entered the core area of the largest city in the United States.



It is reported that the three devices will focus on cancer, heart, nervous system-related diseases and other areas and provide accurate diagnostic solutions to serve patients around the world.



An AMRIC spokesperson said: "Our mission is to use cutting-edge technology and quality services to improve the physical and mental health of our patients. Radiology is both an art and a science. We hope that by partnering with UnitedVision, we can leverage their superior imaging technology to create the best possible service for our patients."



It is understood that not too long ago, The first Total-body PET-CT uEXPLORER and the industry's first "space-time integrated" ultra-clear TOF PET/MR uPMR 790, ultra-high-end CT Tianhe 640, intelligent digital PET-CT and other high-end equipment has been stationed in the United States Michigan State University Innovation Center, Carrollton Regional Medical Center (CRMC), the State University of New York at Stony Brook, the University of Utah Huntsman Cancer Research Center in Salt Lake City and a number of the world's top clinical and scientific research institutions.



Hold high, break through the US, Japan and Europe high-end market

Driven by favorable policies, domestic enterprises gradually break through technical barriers, constantly improve their innovation ability and technical level in the field of medical imaging equipment, product structure from low-end to high-end or even ultra-high-end upgrade, China's "intelligent" medical imaging equipment to overseas markets has become inevitable. United Film Medical is one of the iconic enterprises.



In the overseas market, Lianying Medical adopts the strategy of "high and high", that is, through the world's leading high-end equipment, first break through the high-end markets such as the United States and Japan, and then gradually radiate other overseas regions.



As early as 2013, Lianying Medical began its layout in the United States, setting up a North American research and development center in Houston. In 2018, United Film Medical officially established the North American regional headquarters in Houston, United States, integrating research and development, production and marketing, and formed a team with rich experience in the United States, and officially blew the horn to enter the North American market. With highly competitive technologies and products, Lianying Medical overseas customer satisfaction, brand influence and market share have steadily increased. So far, its products have been deployed in the United States University of California Davis (hereinafter referred to as "UC Davis"), the University of Washington School of Medicine, the University of Texas McGovern School of Medicine and other world-renowned universities and scientific research institutions. As one of the first users of United Image Medical to enter the North American market, Memorial MRI&Diagnostic, a high-end imaging center, has successively introduced a total of 12 products of United Image Medical.



As a global nuclear medicine power, Japan also plays an important role in the field of high-end medical equipment. As early as August 2017, United Picture Medical ultra-clear photoguided PET-CT entered Fujita Healthcare University Hospital, the largest single hospital in Japan, and achieved the ice-breaking of large-scale domestic high-end medical equipment in the Japanese market for the first time. Since then, Japan General Nantohoku Hospital and Fujita Health University Hospital have introduced two digital photoguided PET-CT medical devices.



In Europe, the company established a European subsidiary in Poland in 2018 to expand and serve local customers. On May 20, 2022, the uMI 780, the first digital photoguided PET-CT system in Western Europe, was officially installed in the century-old Sacro Cuore Don Calabria Hospital in Italy to help clinical practice and open a new vision for tumor diagnosis and treatment. The above installation marks the official landing of Lianying Medical in the Western European market.



Global talent team to help forward-looking scientific research exploration

"The success of the United Film medical high-end medical equipment to break the high-end market in the United States, Japan and Europe, excellent, leading innovative technology is the key, at the same time, with a high level of scientific research cooperation ability, to meet the forward-looking scientific research needs of top medical research institutions, to carry out deep collaboration source innovation is also very key." Said Zhang Qiang, chairman and chief executive officer of United Film Medical.



Lianying Medical has set up the Future Lab to recruit scientific talents from all over the world. At present, it has jointly undertaken the major project of the National Institutes of Health Brain Program with Yale University and UC Davis, and as an industrial partner, United Image Medical has developed and created a new high-sensitivity brain special PET system for the project, and jointly created the first 2-meter PET-CT with the top molecular imaging team in the United States. Establish a long-term partnership with the Washington University School of Medicine, the birthplace of 17 Nobel Prizes in Medicine, to collaborate on innovation in the field of cardiac magnetic resonance based on Lianying Medical 1.5T MR, and enable cardiac magnetic resonance scanning, processing, film reading and diagnosis through the full stack of AI technology; In collaboration with the McGovern School of Medicine at the University of Texas, PET-CT based on Intervision Medical will explore and develop cardiac imaging technology to advance the field of molecular imaging heart research.



At the 2022 SNMMI (Society for Nuclear Medicine and Molecular Imaging) Annual Meeting, the world's leading and most influential academic conference in the field of nuclear medicine, the UC Davis research team announced a major achievement: Based on the Total-body PET-CT uEXPLORER explorer, the distribution of T cells in patients recovering from COVID-19 has been observed for the first time in a non-invasive manner with the naked eye. It is reported that T cells play a key role in fighting the novel coronavirus, evaluating related immune responses, and vaccine responses.



UC Davis Professor Simon R. Cherry commented, "Based on the two breakthrough benefits of uEXPLORER's high sensitivity and whole-body coverage, we have contributed to several different disease areas. This COVID-19 study shows once again that leading imaging techniques combined with highly specific radiodevelopers can open up new ways to study human mechanisms. We hope that this study will better help clinical understanding of the immune response to COVID-19 in the human body."



Based on high-end, global radiation

"Lianying Medical stands in the global perspective to actively integrate resources and global capacity layout, recruit global talents, promote the international market's recognition and trust in Lianying medical brand, so that China's intelligent manufacturing and Chinese technology benefit a wider range of people around the world." Zhang Qiang said.



Up to now, the company has established a sales network in the United States, Japan, Poland, Australia, New Zealand, South Korea, South Africa, Morocco, Malaysia and other countries and regions around the world, and the company's products have successfully entered the United States, Japan, Italy, New Zealand, Poland, India, South Korea and other 53 countries and regions.



As one of the top three regional markets in the world with strong demand for high-end medical equipment, the Asia-Pacific region has also made frequent moves.



In August this year, Malaysia's top private hospital Sunway Medical Center introduced the advanced digital PET-CT uMI 780 of United Image Medical, based on the first-class equipment of United Image Medical, the expert teams and medical professionals of both sides will explore more possibilities for clinical and scientific research. The center will also become an important fulcrum for United Film Medical to expand its territory in Southeast Asia.



The medical footprint of United Film is spread across all important cities in India. According to public information, Medicover Hospitals, Mahajan Imaging & Diagnostics, Advantage Imaging and other well-known local medical groups in India are working with United Image Medical to promote the application of high-end medical technology in India. In 2021, China's intelligent digital PET-CT for the first time in the Indian market to reach the first new share.



Dr Harsh Mahajan, former President of the Radiological Society of India and a pioneer in radiology in India, said: "Partnering with United Vision Medical will open up a whole new track for innovative high-end imaging technologies and AI solutions!"



Lianying Medical said that in the future, the company will further deepen the global marketing system, strengthen the construction of overseas localization platform capabilities, seize the opportunity of the transformation and upgrading of China's high-end medical equipment manufacturing industry and uphold the market strategy of "high and high", and drive the breakthrough of the whole line of products with the breakthrough of high-end equipment, and continue to improve the company's comprehensive competitiveness and market coverage.

 

[ym888]

The Obesity Nightmare
According to CDC data in 2012, the United States has become one of the "most obese" developed countries in the world, with 35.7% of its adults and 17% of its children suffering from obesity.
Patients with extreme obesity are usually suffering from other diseases, making them often unable to enter examination equipment smoothly. Their body shape restrictions mean that they have to endure the pains of diseases. Besides, people with claustrophobia, oversized athletes, pregnant women, rickets patients and other groups with special examination needs also face similar problems. But now, they have a new choice.
Recently, Memorial MRI & Diagnostic, a high-end imaging center located in Texas, introduced the world's first 75cm, ultra-wide-bore 3.0T uMR Omega. Compared with the mainstream and standard 60cm-bore MR machines in the industry, uMR Omega expands the bore to 75cm, providing an unprecedented spacious scanning experience similar to "first-class cabin". What's more, it can also accommodate 300kg overweight patients, and provide wider application space for the MR examination of shoulders, elbows, hip joints and other parts far away from the center of the human body.
John is an oversized rugby player. High confrontation intensity on the pitch has made him suffer from joint injuries, which requires high-definition image examinations. However, conventional MR cannot complete the scanning of complex positions such as eccentric joints. As a result, he had to seek medical service in other states. But, the arrival of uMR Omega makes it possible for him to easily complete body scanning at his doorsteps.
*To protect the privacy of patients, their real names or photos are not used in this article.
The Twelfth Cooperation

This is not the first cooperation between United Imaging and Memorial MRI & Diagnostic, a high-end imaging center dedicated to providing accurate, efficient and personalized diagnostic and therapeutic services. Since its establishment, Kim, its founder, has been constantly looking for more universal and intelligent innovative products, and what she finds is United Imaging. In the past three years, Memorial MRI & Diagnostic has introduced United Imaging's full-line products, including MR, MI, CT and XR products, for 12 consecutive times, becoming a "staunch supporter" of the Chinese brand.
A 5cm Chasm
To achieve the leap to "first-class cabin" experience, it is imperative to overcome the root causes of technical barriers. For decades, engineers around the world have been trying to increase the bore limit of high-field superconducting magnetic resonance. Every 1cm of expansion creates numerous technical problems. How to maintain quality imaging and system stability while expanding the bore looks like an insurmountable "chasm"!
United Imaging's uMR Omega engineers have addressed problems in the source of technology and identified a new technical path to "resolve the problem with ingenuity": create an unprecedented ultra-wide 97cm-inner-diameter net magnet architecture, and achieve a magnetic field uniformity comparable to or even better than that of the traditional 70cm wide-bore magnetic resonance while expanding the bore; build the industry's first GPA with 3.5MW peak power, equivalent to that of 13 V8 engines, which can easily harness advanced clinical research applications and even high-precision radiotherapy simulation positioning.

Bigger Size Generates New Possibilities
The unprecedented 75cm bore increases the volume by 33%, providing new "first-class cabin" experience.

The industry's first "starry sky" environment turns the long magnetic resonance scanning into an immersive "Star Watching Experience" to relieve anxiety and claustrophobia.

Combination with the uAIFI Technology assisted by AI allows fast and accurate examinations with improved patients' comfort, ushering in an era of "Brain-inspired".

Todd Greene
COO of Memorial MRI and Diagnostic

"We look for the right value and technology, so we have strategically aligned with United Imaging in some of our very strategic, high-end imaging modalities to provide best-in-class technology for our patients, You have to select technology that is scalable, relevant, and very usable. But, equipment is just equipment if it's not working well, if it's not upgraded in a timely way. We really look for a company that can walk with us down our path, be it quality, service, or our goals around providing access to the best MRI exams to our community. We look for all of those components to drive excellence."

 

[RoaringTigerHiddenDragon]

China's "intelligent" high-end medical equipment has entered the core area of New York, and the overseas development of United Film Medical has accelerated

2022-11-01 20:44:01

Recently, The first 75cm ultra-large aperture 3.0T magnetic resonance uMR Omega, ultra-high-end 640-slice CT Tianhe 640 and intelligent digital PET-CT uMI 550 independently developed by Shanghai Lianying Medical Technology Co., LTD. (hereinafter referred to as "Lianying Medical") have successively entered AMRIC in the Upper East Side of Manhattan, New York, USA (Advanced Medical & Research Imaging Center), this is the first time that China's high-end medical equipment has entered the core area of the largest city in the United States.



It is reported that the three devices will focus on cancer, heart, nervous system-related diseases and other areas and provide accurate diagnostic solutions to serve patients around the world.



An AMRIC spokesperson said: "Our mission is to use cutting-edge technology and quality services to improve the physical and mental health of our patients. Radiology is both an art and a science. We hope that by partnering with UnitedVision, we can leverage their superior imaging technology to create the best possible service for our patients."



It is understood that not too long ago, The first Total-body PET-CT uEXPLORER and the industry's first "space-time integrated" ultra-clear TOF PET/MR uPMR 790, ultra-high-end CT Tianhe 640, intelligent digital PET-CT and other high-end equipment has been stationed in the United States Michigan State University Innovation Center, Carrollton Regional Medical Center (CRMC), the State University of New York at Stony Brook, the University of Utah Huntsman Cancer Research Center in Salt Lake City and a number of the world's top clinical and scientific research institutions.



Hold high, break through the US, Japan and Europe high-end market

Driven by favorable policies, domestic enterprises gradually break through technical barriers, constantly improve their innovation ability and technical level in the field of medical imaging equipment, product structure from low-end to high-end or even ultra-high-end upgrade, China's "intelligent" medical imaging equipment to overseas markets has become inevitable. United Film Medical is one of the iconic enterprises.



In the overseas market, Lianying Medical adopts the strategy of "high and high", that is, through the world's leading high-end equipment, first break through the high-end markets such as the United States and Japan, and then gradually radiate other overseas regions.



As early as 2013, Lianying Medical began its layout in the United States, setting up a North American research and development center in Houston. In 2018, United Film Medical officially established the North American regional headquarters in Houston, United States, integrating research and development, production and marketing, and formed a team with rich experience in the United States, and officially blew the horn to enter the North American market. With highly competitive technologies and products, Lianying Medical overseas customer satisfaction, brand influence and market share have steadily increased. So far, its products have been deployed in the United States University of California Davis (hereinafter referred to as "UC Davis"), the University of Washington School of Medicine, the University of Texas McGovern School of Medicine and other world-renowned universities and scientific research institutions. As one of the first users of United Image Medical to enter the North American market, Memorial MRI&Diagnostic, a high-end imaging center, has successively introduced a total of 12 products of United Image Medical.



As a global nuclear medicine power, Japan also plays an important role in the field of high-end medical equipment. As early as August 2017, United Picture Medical ultra-clear photoguided PET-CT entered Fujita Healthcare University Hospital, the largest single hospital in Japan, and achieved the ice-breaking of large-scale domestic high-end medical equipment in the Japanese market for the first time. Since then, Japan General Nantohoku Hospital and Fujita Health University Hospital have introduced two digital photoguided PET-CT medical devices.



In Europe, the company established a European subsidiary in Poland in 2018 to expand and serve local customers. On May 20, 2022, the uMI 780, the first digital photoguided PET-CT system in Western Europe, was officially installed in the century-old Sacro Cuore Don Calabria Hospital in Italy to help clinical practice and open a new vision for tumor diagnosis and treatment. The above installation marks the official landing of Lianying Medical in the Western European market.



Global talent team to help forward-looking scientific research exploration

"The success of the United Film medical high-end medical equipment to break the high-end market in the United States, Japan and Europe, excellent, leading innovative technology is the key, at the same time, with a high level of scientific research cooperation ability, to meet the forward-looking scientific research needs of top medical research institutions, to carry out deep collaboration source innovation is also very key." Said Zhang Qiang, chairman and chief executive officer of United Film Medical.



Lianying Medical has set up the Future Lab to recruit scientific talents from all over the world. At present, it has jointly undertaken the major project of the National Institutes of Health Brain Program with Yale University and UC Davis, and as an industrial partner, United Image Medical has developed and created a new high-sensitivity brain special PET system for the project, and jointly created the first 2-meter PET-CT with the top molecular imaging team in the United States. Establish a long-term partnership with the Washington University School of Medicine, the birthplace of 17 Nobel Prizes in Medicine, to collaborate on innovation in the field of cardiac magnetic resonance based on Lianying Medical 1.5T MR, and enable cardiac magnetic resonance scanning, processing, film reading and diagnosis through the full stack of AI technology; In collaboration with the McGovern School of Medicine at the University of Texas, PET-CT based on Intervision Medical will explore and develop cardiac imaging technology to advance the field of molecular imaging heart research.



At the 2022 SNMMI (Society for Nuclear Medicine and Molecular Imaging) Annual Meeting, the world's leading and most influential academic conference in the field of nuclear medicine, the UC Davis research team announced a major achievement: Based on the Total-body PET-CT uEXPLORER explorer, the distribution of T cells in patients recovering from COVID-19 has been observed for the first time in a non-invasive manner with the naked eye. It is reported that T cells play a key role in fighting the novel coronavirus, evaluating related immune responses, and vaccine responses.



UC Davis Professor Simon R. Cherry commented, "Based on the two breakthrough benefits of uEXPLORER's high sensitivity and whole-body coverage, we have contributed to several different disease areas. This COVID-19 study shows once again that leading imaging techniques combined with highly specific radiodevelopers can open up new ways to study human mechanisms. We hope that this study will better help clinical understanding of the immune response to COVID-19 in the human body."



Based on high-end, global radiation

"Lianying Medical stands in the global perspective to actively integrate resources and global capacity layout, recruit global talents, promote the international market's recognition and trust in Lianying medical brand, so that China's intelligent manufacturing and Chinese technology benefit a wider range of people around the world." Zhang Qiang said.



Up to now, the company has established a sales network in the United States, Japan, Poland, Australia, New Zealand, South Korea, South Africa, Morocco, Malaysia and other countries and regions around the world, and the company's products have successfully entered the United States, Japan, Italy, New Zealand, Poland, India, South Korea and other 53 countries and regions.



As one of the top three regional markets in the world with strong demand for high-end medical equipment, the Asia-Pacific region has also made frequent moves.



In August this year, Malaysia's top private hospital Sunway Medical Center introduced the advanced digital PET-CT uMI 780 of United Image Medical, based on the first-class equipment of United Image Medical, the expert teams and medical professionals of both sides will explore more possibilities for clinical and scientific research. The center will also become an important fulcrum for United Film Medical to expand its territory in Southeast Asia.



The medical footprint of United Film is spread across all important cities in India. According to public information, Medicover Hospitals, Mahajan Imaging & Diagnostics, Advantage Imaging and other well-known local medical groups in India are working with United Image Medical to promote the application of high-end medical technology in India. In 2021, China's intelligent digital PET-CT for the first time in the Indian market to reach the first new share.



Dr Harsh Mahajan, former President of the Radiological Society of India and a pioneer in radiology in India, said: "Partnering with United Vision Medical will open up a whole new track for innovative high-end imaging technologies and AI solutions!"



Lianying Medical said that in the future, the company will further deepen the global marketing system, strengthen the construction of overseas localization platform capabilities, seize the opportunity of the transformation and upgrading of China's high-end medical equipment manufacturing industry and uphold the market strategy of "high and high", and drive the breakthrough of the whole line of products with the breakthrough of high-end equipment, and continue to improve the company's comprehensive competitiveness and market coverage.

This will soon go the semiconductor way as more CCP thousand talents thieves are arrested. The Houston consulate was shut down for this very same reason. By the way china itself imports 70% of its biomedical devices, showing it has a long way to go. Now with China cut off from critical tech in all areas, it is going to fall behind in biomedical innovation too. Just a matter of time.
‘FDI in biomedical technology is already shifting India and other countries.

 

[ym888]

This will soon go the semiconductor way as more CCP thousand talents thieves are arrested. The Houston consulate was shut down for this very same reason. By the way china itself imports 70% of its biomedical devices, showing it has a long way to go. Now with China cut off from critical tech in all areas, it is going to fall behind in biomedical innovation too. Just a matter of time.
‘FDI in biomedical technology is already shifting India and other countries.

The biotech industry in China is relatively nascent. Even though the country’s healthcare market is the second largest globally1, biotech-driven treatments account for only 12% of the China’s total drug market.2 Companies in this space are also far behind their global counterparts both in terms of revenue and R&D investments. In 2019 for example, sales of the top ten biotech drugs (biologics) globally were in the range of USD 6 to 20 billion while Chinese biologic sales were in the range of RMB 3 to 5 billion (see Chart 1 and 2).

Source: Frost & Sullivan, Morgan Stanley Research
Yet research firms expect that the mainland biotech market will be worth US$96 billion by 2023 (from US$40 billion in 2018).3 This is in part due to the country’s rapidly ageing population and affluent middle class that is willing to spend on quality healthcare products and services as outlined in this earlier piece. Chris Liu, Senior Portfolio Manager within Invesco’s China A Investments team summarizes some other factors driving the growth of this market.
History and case for biotech
As recently as five years ago, most new drugs in China whether chemical or biopharmaceutical, came from overseas. Chinese drug makers were instead focused on producing generic drugs (once the global patents on these medicines expired. In 2016, for example, generic drugs had a market share of 95%.4 However, in the past five to ten years, Chinese companies have been moving up the value chain (see Chart 3). Before 2010, the top 20 China healthcare companies were mostly generic drug makers, while from 2010-2020, we saw more biological drug companies emerging in the top 20.

Source: Wind, as of June 2020
Biotech drugs are now favorable as compared to chemical drugs as they have fewer side effects. In 2019 for example, seven out of the top ten bestselling global drugs were biologics (see Chart 1). These drugs are typically used to treat cancer cells and tumors.
Drivers for the interest in biotech:
1. Reduction in the prices of generic drugs
Since 2018, there have been five rounds of National Reimbursement Drug List (NRDL) price negotiations for new drugs (see Table 1). This has been aimed at reducing the price burden for patients looking to get their expenses reimbursed under the national basic medical insurance scheme.

Source: NHSA, Credit Suisse
Consequently, generic drug makers in the country have been pushed to innovate to make up for this margin correction. Large Chinese pharma companies are now spending more on R&D and specifically are looking to innovative areas such as oncology drugs. At the same time biotech companies in China are also emerging with a shorter history and more concentrated product pipeline.
2. Enhancement and streamlining of regulatory standards
The National Healthcare Security Administration (NHSA) was set up in 2018, responsible for managing all basic health insurance schemes in the country. This represented a milestone in China’s health sector reform to further improve the efficiency of the healthcare system in areas such as cost controls, service quality and value for money.5 Since their launch, the NHSA has added more non-generic drugs to the list of those that qualify for patient reimbursement.6 Specifically, anticancer “PD-1” drugs have been included into drug list which are a key focus area for biotech players.7
The National Medical Products Administration (NMPA), a bureau set up for approval process of new drugs, was also rebranded in 2018 and has since been employing a clearer and more efficient drug-approval system based on global standards (while it took much longer to get new drugs approved with the previous system8). This transformation is also expected to shift the healthcare industry’s focus from generic to innovative drug development.9
3. Access to capital
As of mid-2018, Hong Kong’s stock exchange amended its listing rules to allow for qualified biotech companies to list on the exchange without earnings. This was a significant step in providing Chinese biotech firms with more access to capital to fuel R&D. Later in 2019, the Shanghai Stock Exchange officially launched the STAR Market (the Science and Technology Innovation Board), with a focus on supporting high and new technology industries and strategic emerging industries.10 As part of this, the China Securities Regulatory Commission has been able to fast-track approval for the listing of high-tech unicorns including biotechs.11 Apart from public channels, private equity and venture capital investment in this space is also growing rapidly.12
4. Prospect of global market demand
Onshore biotech firms are currently competing heavily with foreign players to capture domestic market share. However, many are also setting their sights farther afield and are looking to tap into the vast global market in the long run. In 2019 for example, a domestic biotech company’s lymphoma treatment was approved by the US FDA - the first China-discovered innovative cancer drug to win such approval.13 Earlier this year the same company signed a $2.2-billion deal with a global pharmaceutical giant to license their PD-1 drug in major markets outside of the country.14 A few other biotech companies have also had licensing deals with global MNCs to obtain FDA approval for their new biological drugs to be sold in the US and other countries.
Unique opportunities in China’s biotech sector
We believe the growing biotech market represents an untapped opportunity for investors. Chinese biotech companies have a few competitive advantages that could help them gain more market share in the future:
1) High quality sizeable domestic talent pool with STEM-related backgrounds (9 million fresh graduates in China in 202115)
2) Cost of onshore clinical trials is lower than other countries which can speed up the drug development process. With a population of 1.4 billion people, the cost of summoning a sizeable patient sample is lower.16
3) China’s expertise in AI can give biotech companies a competitive edge to speed up the drug discovery phase (and can make up for what they lack in experience relative to US firms).

 

[ym888]

A booming market: Why the Chinese biotech sector is primed for growth
By Juliet Martin

A prime opportunity for China’s domestic drug development industry to capitalise on the growing need for new therapeutics.
Established itself as the second largest market in the world, behind only the United States, the Chinese pharmaceutical sector is second to the US market and is forecasted to continue its growth to reach USD 300.9bn by 2025 at a healthy 12.2% CAGR[1]. These growth projections are built upon a strong foundation, with the country increasing its expenditure on healthcare from 5.2% in 2012 to 6.64% by 2019 of its GDP, according to GlobalData. Furthermore, the country’s over 60s population is anticipated to reach 360m by 2030 compared with 210m in 2020, according to GlobalData, bringing a prime opportunity for China’s domestic drug development industry to capitalise on the growing need for new therapeutics.
Free Whitepaper
State of the Global Biotech Landscape: Where the Opportunities Lie
The last five years has been a unique time period for the global biotech and pharmaceutical landscape, encompassing the COVID-19 pandemic and all the challenges and opportunities it created. Clinical trials have seen continued growth, with uneven geographical...
Read more

Submit
In the Chinese government’s “Made in China 2025” industrial strategy, the biotech sector is expected to prove a key focal point[2]. Supporting this initiative, a series of policies and regulatory reforms have been implemented in order to streamline the drugs approval process and foster a new culture that enables innovation to flourish. In addition, the State Administration for Market Regulation (SAMR) has revised the Administration Measures for Drug Registration to streamline the complexity of new therapy approval and reduce the cost burden on domestic drug development industry.
At the same time, the country’s wider pharmaceutical regulations were revised and brought in line with global standards. This culminated in the regulations being approved by the International Council for Pharmaceutical for Human Use in 2017, making the market more attractive to domestic and foreign investors alike[3].

Fresh investment and wider reimbursement
This has prompted a surge in capital investment into the sector, with the market value of public listings across the Nasdaq, Hong Kong Stock Exchange and Shanghai Stock Exchange Science and Technology Innovation Board (STAR) growing from just USD 3bn back in 2016 to more than USD 380bn by July 2021, according to McKinsey[4]. Furthermore, of the 10 largest biopharma initial public offerings globally between 2018 and 2020, seven originated from China[5].
This fresh influx of investment from the capital markets has also been strengthened by reforms made to the National Reimbursement Drug List (NRDL) that has expanded the access to innovative drugs through the country’s basic medical insurance coverage.
In 2020, the expansion of the NRDL to include 2,800 drugs resulted in an average price cut of 51%, which has been followed up with a new NRDL in March 2021 that is designed to further increase access and reduce the cost of access to new drugs, of which many will come from the biopharma sector.
In support of this, the government has also vastly increased the resources that it has dedicated to approving these new drugs, with the headcount at the Centre for Drug Evaluation (CDE) rising from just 150 in 2015 to more than 700 by the end of 2018.
The manufacture of generics accounted for 90% of marketed products in June 2021, according to GlobalData. The focus in China is now shifted towards the development and production of biosimilars and other more innovative drugs by utilising these regulatory changes and increasing investor interest.

The push for biosimilars is expected to be one of the key beneficiaries of the regulatory reforms with the creation of biosimilar pathway in 2015, which had led to the approval of 30 products and the development of more than 100 in the clinical development pipeline as of June 2021[6].
The key to enable this more innovative approach to biosimilar development has been a more scientific approach towards clinical trial data requirement for local manufactured biosimilars with the National Medical Products Administration (NMPA) formally approved the use of data from non-Chinese clinical trials.
The use of foreign data biopharma firms can draw from, alongside the other reforms made, have opened up unprecedented opportunities within China for the biotech market.
“These are tremendous initiatives that are seen as extremely positive for biotechs,” explains Andy Liu, Head of China for Novotech, the Asia Pacific Contract Research Organization (CRO). “The expedited regulatory approval and the updated communication channel provide biotech’s with a transparent and equal platform for discussing the drug development plan.”
Explaining that such measures led the NMPA to approve eight break-through therapies in 2021 – including three accelerated approvals and 12 fast-tracked approvals – Liu is confident that the market will only continue to grow.
The forecasted growth for both the pharmaceutical and biopharma sectors offers a lucrative future, and provides a healthy ecosystem with an increasing competition on skilled labour and a continuously increase of development costs.
“As part of this booming market, there are also challenges,” explains Liu. “The entire drug development industry is facing the challenge of a shortage of talents to accommodate sustainable growth.
“As the cost of labour continues to surge, Novotech is fully leveraging our global network by deploying a global shared service centre in China where our well-established systems and processes are able to bring down costs without compromising on quality.”

 

[Azaad]

Chinese police detain wealth management staff at the heavily indebted developer Evergrande

Evergrande is the world’s most heavily indebted real estate developer, at the center of a property market crisis that is dragging on China’s economic growth.

www.thehindu.com

Will the directors of Evergrande disappear for a few weeks , months , years or forever ? What's the inside story from MSS ? @SexyChineseLady ; @rockdog ; @ym888

 

[ym888]

Chinese police detain wealth management staff at the heavily indebted developer Evergrande

Evergrande is the world’s most heavily indebted real estate developer, at the center of a property market crisis that is dragging on China’s economic growth.

www.thehindu.com

Will the directors of Evergrande disappear for a few weeks , months , years or forever ? What's the inside story from MSS ? @SexyChineseLady ; @rockdog ; @ym888

directors of Evergrande？

They're still working

 

[Azaad]

directors of Evergrande？

They're still working

So are they working or aren't they working ? Silly question to be honest. What I should be asking is are they alive or ....

 

[MiG-29SMT]

The European Union needs to investigate Chinese support for electric vehicles as a result of the massive subsidies it provides the industry, according to the head of the bloc’s executive arm.

We like competition but it has to be fair competition,” European Commission President Ursula von der Leyen said in an interview with Bloomberg. “What we see is massive subsidies in the EV sector in China, which is of course unleveling our playing field.”


The commission announced an anti-subsidy probe last week, which could lead not only to tariffs on made-in-China EV imports, but retaliation from Beijing as well. The EU’s probe underscores its difficulties in fostering trade ties with the world’s second-biggest economy while also guarding against perceived supply chain and national security risks.

Beijing has called the move, which may trigger import tariffs on Chinese vehicles, “a naked act of protectionism.” If tariffs are imposed, China’s most powerful response would be to restrict access to its vast market — something that would hit German automakers hardest as they sold 4.6 million cars there last year.

The EU’s trade chief Valdis Dombrovskis will shortly head to China to discuss pressing issues including the EV subsidies, von der Leyen said.

German Foreign Minister Annalena Baerbock told Bloomberg Television on Sunday that the EU must reduce its reliance on China and that she supports the EVs investigation.“If you are bound too closely it can endanger yourself.” She added that “cutting down on our dependency” was necessary with a country like Russia that invaded Ukraine, “but also now with regard to China.”

The investigation marks the first concrete step to beat back rival state support for green technologies after more than a year of ever larger subsidies in the US, China, the UK and Europe.

The EV probe against China is part of a broader EU effort to “de-risk” the relationship without “de-coupling.” This has included restricting sales of high-end semiconductors and implementing export controls related to quantum computing and artificial intelligence. The bloc has also put in place new instruments to address China’s coercive practices.

With China the biggest market for Volkswagen AG and other German carmakers, tangling with Beijing could be risky. BMW AG imports its battery-powered iX3 from China, with Mini models due to follow. The Munich-based carmaker generated 33% of its operating profit from the country last year, followed by Porsche, VW and Mercedes-Benz, analysts at Citigroup Inc. estimated in a note late last month.

Speaking of the state support provided to the Chinese EV industry, von der Leyen said: “We don’t accept this in the internal market for our companies so we also don’t accept it for Chinese companies and therefore the investigation now for subsidies for EVs in China.”

EU’s Von Der Leyen Says Massive China Subsidies for EVs Requires a Probe

(Bloomberg) -- The European Union needs to investigate Chinese support for electric vehicles as a result of the massive subsidies it provides the industry, according to the head of the bloc’s executive arm.Most Read from BloombergVegas’ Newest Resort Is a $3.7 Billion Palace, 23 Years in the...

www.yahoo.com

 

[MiG-29SMT]

Britain cannot follow blundering Von der Leyen into dead-end protectionism
Jeremy Warner
Sat, September 16, 2023 at 8:00 PM GMT+9·6 min read
0

Ursula von der leyen
For once it is possible largely to agree with what the Chinese had to say about it, characteristically blunt and bellicose though it was.
The European Union, China’s ministry of commerce said, was guilty of “a naked protectionist act” in launching a subsidies investigation into China’s electric car industry.
In her annual state of the union address, Ursula von der Leyen, President of the European Commission, made it abundantly clear that Chinese EVs are very likely soon to be subjected to punishing EU tariffs and other forms of import restriction – all possibly dressed up under the catch-all of a carbon border tax.
China’s all-out assault on the global market for EVs is admittedly a matter of some concern, with tens of thousands, possibly millions, of jobs riding on it. But when the EU’s first response to industrial competition is to reach for the protectionist playbook, you know that this is an economy in serious trouble. Protectionism is for economic losers, not winners.

Yes, of course China has been heavily subsidising its EV industry, which it sees as an important alternative driver of economic growth now that it has exhausted the old rocket boosters of an unrestrained construction boom. We all know this. In that sense, there is nothing to investigate.
After the debacle of solar panels, moreover, the EU has good reason to worry. Having stolen the original technology from Germany, China now dominates the global market for solar energy. Nobody else gets a look in.
But though late to the party, the EU, the US, and even the UK in its own penny-pinching way, have also all been lavishing government subsidies on “green” industries, including EVs. State aid rules have been thrown to the wind in supposed pursuit of energy transition goals.
Yet sadly, the Chinese have stolen a march, and are already ahead of the game. Europe has been caught napping, having failed properly to think through the industrial, economic and geopolitical implications of its dash for net zero.
There is no denying China’s breathtaking double standards in tapping into Europe’s confusion. On the one hand it ruthlessly exploits the self inflicted harm of Europe’s commitment to early phasing out the internal combustion engine, while on the other it fails to abide by the same climate change targets itself, and moreover hugely adds to the global emissions problem by expanding the coal-fired generation it needs to fuel mushrooming EV production.
One rule for us, it seems, and a different one for them.
But is this sufficient reason to block Chinese competition? On the basis that almost anything proposed by Von der Leyen is bound to be wrong alone, we can safely say that protectionism is not the solution. Britain must be ultra careful not to get caught up in Von der Leyen’s delusions.
Going by the name of Rose Ladson when studying at the London School of Economics, and also known simply as UVL, Von der Leyen is a kind of living caricature of the Brussels machine – clever, charming, multilingual, liberally minded, hugely well connected and plausible, but also entitled and essentially useless with a string of failures and calamitous misjudgments to her name.
She would never have been commission president in the first place but for the fact that she messed up so badly as defence minister in her native Germany that it destroyed her chances of succeeding Angela Merkel as German chancellor, a position she once seemed predestined to occupy.
So she was put out to pasture in Brussels instead, where theoretically she couldn’t do any more harm. No such luck. Her handling of Europe’s Covid vaccine rollout was a case study in mismanagement and incompetence, culminating in a completely crass attempt to use the Northern Ireland Protocol to stop AstraZeneca complying with its contractual obligations to the UK by diverting product to Britain.
No matter; Von der Leyen floats effortlessly from one blunder to the next as if none of it were her fault, which in a sense it isn’t. It would tax the wisdom of Solomon to deliver effective policy in a union of 27, often fractious, member states – soon to be swollen to an even more unmanageable 30, and eventually 35.
Yet by giving way to French pressure for protectionist measures, Von der Leyen has not only upset the Chinese but even many of her own countrymen back home in the industrial heartlands of the Rhine. German carmakers, most of which sell heavily to China and have extensive operations there, are understandably furious.
Conscious that a trade war would hit business in China, Mercedes-Benz has broken cover to condemn the move as counterproductive, while Bosch, the world’s largest automotive supplier, said that a race for punitive tariffs and trade barriers would only have losers.
Here in Britain, protectionist measures to safeguard our car industry are even less appropriate. Government policy is firmly focused on maintaining some kind of an automotive sector by helping carmakers transition to EVs, and there have indeed been some minor successes. BMW has announced it is to build an all electric version of the Mini here in Britain, and buttressed by lorry loads of government money, Jaguar Land Rover has announced plans for a £4bn electric battery plant.
As for Chinese marques – within reason, let them come. All competition is good, and if they force UK manufacturers to up their game, so much the better. As things stand, many Chinese models are both cheaper than most European counterparts and superior to them, so why would you deprive British consumers of these benefits? Let’s just take the Chinese subsidy, and use it to our own advantage.
There are admittedly two obvious objections to the purity of this free-trade approach. One is that if the EU continues down its protectionist road, but the UK doesn’t follow suit, Britain might become a dumping ground for China’s excess EV production.
Furthermore, an open borders policy might further increase Britain’s economic dependence on China, raising further security concerns around a potentially hostile power. And once China had monopolised our market by undercutting and closing down the local competition, it could then whack up its prices and milk the UK economy accordingly.
Yet these concerns ought to be manageable, and it is a matter of fact that if Chinese automobile companies want any kind of a long-term future in British and European markets, they will eventually have to invest heavily in them, rather in the same way as Japanese car manufacturers did in the UK under Margaret Thatcher.
On that note, it is about time that Elon Musk’s Tesla started ponying up with some significant investment in the UK, where it sells almost as many cars as Germany.
In any case, having left the EU, it would be perverse to simply mirror its vulnerabilities by cowering behind high protectionist walls. We must remain as open as possible, even to China.

EU’s Von Der Leyen Says Massive China Subsidies for EVs Requires a Probe

(Bloomberg) -- The European Union needs to investigate Chinese support for electric vehicles as a result of the massive subsidies it provides the industry, according to the head of the bloc’s executive arm.Most Read from BloombergVegas’ Newest Resort Is a $3.7 Billion Palace, 23 Years in the...

www.yahoo.com

 

[ym888]

So are they working or aren't they working ? Silly question to be honest. What I should be asking is are they alive or ....

If someone owes a lot of money



Then he will be perfectly safe

 

[Azaad]

If someone owes a lot of money



Then he will be perfectly safe

You mean it's perfectly alright to skim money from the state thru their banks & the people at large & because the sums owed are too large , nothing's going to happen. Sounds like precisely the modus operandi of the CCP. Thanks for clarifying.

 

[ym888]

You mean it's perfectly alright to skim money from the state thru their banks & the people at large & because the sums owed are too large , nothing's going to happen. Sounds like precisely the modus operandi of the CCP. Thanks for clarifying.

Aggressive over-borrowing is a common phenomenon in market economies



Any country has it



The market economy is not perfect

 

[Azaad]

Aggressive over-borrowing is a common phenomenon in market economies



Any country has it



The market economy is not perfect

Not on the scale it's happening in China or in the case of Evergrande. You're truly in a league of your own . I guess all those multi billion USD townships , expressways to nowhere , thousands of kms of HSR all economically unviable had to come at a price . Which is ultimately being paid by the Chinese people & this is where we are at the moment .

 

[ym888]

Not on the scale it's happening in China or in the case of Evergrande. You're truly in a league of your own . I guess all those multi billion USD townships , expressways to nowhere , thousands of kms of HSR all economically unviable had to come at a price . Which is ultimately being paid by the Chinese people & this is where we are at the moment .

When you reach 19T



You wouldn't care

 

[Azaad]

When you reach 19T



You wouldn't care

Assuming you've reached 19 T


You will see that everyone cares once such projects start unravelling not when the going is good .

 

[ym888]

Assuming you've reached 19 T


You will see that everyone cares once such projects start unravelling not when the going is good .

If you open the old newspaper



You'll find similar questions raised every year

 

[ym888]

Will NearLink replace Bluetooth?


Huawei Nearlink launched, new wireless technology far ahead of Bluetooth
05/08 02:36
4225 4 6

Today, Huawei officially launched a new generation of short-range wireless connection technology – NearLink. This technology brings together the collective collaboration of more than 300 leading enterprises and institutions at home and abroad.
It also uses a set of standards to integrate the advantages of traditional wireless technologies such as Bluetooth and WIFI, and its performance is significantly stronger.

Compared with traditional wireless connections, Huawei Nearlink has the advantages of 60% lower power consumption, 6 times higher speed, 1/30 delay, and 10 times higher number of network connections.
Nearlink can be used in various scenarios such as consumer electronics, smart homes, electric vehicles, and industrial smart manufacturing to provide a stronger HarmonyOS experience for the Internet of Everything.
In terms of smartphones, PCs, cars, and others, it can create lower latency, lower power consumption, wider coverage, and safer connection technologies for users.

 

[ym888]

Huawei Nearlink new wireless technology will debut on September 25

Published
24 hours ago
on
September 19, 2023
By
Yash Mishra

Huawei Nearlink wireless technology is set to debut on September 25 with new products launching at the Autumn 2023 flagship unveiling conference. Last month, Huawei announced Nearlink and its capabilities at the HDC 2023 software event.
According to the information, Huawei MatePad Pro 13.2 will be one of the products taking advantage of this new wireless tech out of the box.
With Nearlink, Huawei is looking forward to the revolution in the area of wireless transmission capability. It’s revealed that Nearlink takes about 60% less power than traditional wireless transmission technologies. It has 6x faster speed, 1/30 delay, and 10x network connection support. These are some amazing qualities of the Nearlink.
Nearlink uses a set of standards to integrate the advantages of traditional wireless technologies including Bluetooth. It can solve the needs of smart devices and smart homes that cannot meet the ultimate experience such as latency and reliability in some subdivided scenarios.

For example, the air interface delay of an e-sports mouse can be increased from milliseconds to microseconds. In addition, with high bandwidth and anti-interference capabilities, lossless audio which has been difficult to achieve with Bluetooth headsets in the past has become a reality.
In the smart travel situation, the positioning accuracy of Nearlink digital car keys has changed from meter level to decimeter level. Still, the tech has not been seen in action and we would like to see all of these capabilities of Huawei Nearlink as its debut will happen next week.

 

[rockdog]

Huawei Nearlink new wireless technology will debut on September 25

Published
24 hours ago
on
September 19, 2023
By
Yash Mishra

• • 
    
  • 
    

Huawei Nearlink wireless technology is set to debut on September 25 with new products launching at the Autumn 2023 flagship unveiling conference. Last month, Huawei announced Nearlink and its capabilities at the HDC 2023 software event.
According to the information, Huawei MatePad Pro 13.2 will be one of the products taking advantage of this new wireless tech out of the box.
With Nearlink, Huawei is looking forward to the revolution in the area of wireless transmission capability. It’s revealed that Nearlink takes about 60% less power than traditional wireless transmission technologies. It has 6x faster speed, 1/30 delay, and 10x network connection support. These are some amazing qualities of the Nearlink.
Nearlink uses a set of standards to integrate the advantages of traditional wireless technologies including Bluetooth. It can solve the needs of smart devices and smart homes that cannot meet the ultimate experience such as latency and reliability in some subdivided scenarios.

For example, the air interface delay of an e-sports mouse can be increased from milliseconds to microseconds. In addition, with high bandwidth and anti-interference capabilities, lossless audio which has been difficult to achieve with Bluetooth headsets in the past has become a reality.
In the smart travel situation, the positioning accuracy of Nearlink digital car keys has changed from meter level to decimeter level. Still, the tech has not been seen in action and we would like to see all of these capabilities of Huawei Nearlink as its debut will happen next week.

The report shows that Huawei continues to strengthen investment in R&D, with an annual expenditure of 23.51 billion USD in 2022

Huawei secures $93.5 billion in revenue in 2022

Addis Ababa, March 31, 2023 (FBC) - Huawei has released its 2022 Annual Report today. The company, in its annual report, indicates that operations throughout 2022, have helped it generate 93.5 billion USD in revenue and 5.18 billion USD in net profit

www.fanabc.com

This is huge amount, it's like 16th if Huawei were nation, similar amount to Spain.

List of sovereign states by research and development spending - Wikipedia

en.wikipedia.org